William Burke, MD
Gynecologic Oncology · Paramus, NJNPI 1932154739
Payments from drug & device makers
What this record shows
This record is dominated by education: $8,000 of the $9,498 with a category attached, or 84.2%. Intuitive Surgical accounts for 94.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $8,325 and has fallen 99.7% since, to $24 in 2025.
Across 17 payments — averaging $558.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- Myriad Genetic Laboratories, Inc.$300
- Abbott$126
- Medtronic$65
- Immunogen, Inc.$25
- Clovis Oncology, Inc.$22
Across 106 payments — averaging $18,913 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1.4M
- Tesaro, Inc.$550K
- Ferring International Pharmascience Center US$11K
What the payments were for
- Travel & lodging$6357%
- Food & beverage$8639%
- Education$8,00084%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $8,960 |
| Myriad Genetic Laboratories, Inc. | 5 | $300 |
| Abbott | 1 | $126 |
| Medtronic | 2 | $65 |
| Immunogen, Inc. | 1 | $25 |
| Clovis Oncology, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,498 in reported general payments places this provider in the 85th percentile of 45 gynecologic oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 13 | $1,085 |
| Letrozole | 22 | $145 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Paramus
- Sharyn LewinTeaneck$968K
- Scott RichardFlorham Park$84K
- Joyce VarughesePennington$16K
- James BosscherNeptune$13K
- Daniel TobiasMorristown$11K
- Karim ElsahwiNeptune$11K
- Maria Schiavone ForlenzaTeaneck$8K
- Thad DenehyWest Orange$5K
- Shannon TomitaMorristown$4K
- Brooke MeelheimWest Orange$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.